

K971637

**510(K) Submission for  
Oxoid Antimicrobial Susceptibility Test Disc**

**COMPOUND SULPHONAMIDES**

**OXOID LTD**

---

**510(K) Summary**

DEC 23 1997

**510(K) Number** : K971637

**Product Name** : Compound Sulphonamides Susceptibility Test Disc

**Manufacturer** : Oxoid Limited  
Wade Road  
Basingstoke  
Hants RG24 8PW  
England

**Substantial Equivalence** :

Oxoid Compound Sulphonamide Antimicrobial Susceptibility Test Discs are substantially equivalent to other antimicrobial susceptibility test discs on the market.

**Product** : BBL Sensi-Disc Sulphonamides 300µg/mL  
Sensi -Disc - Antimicrobial Susceptibility Test Disc

**Manufacturer** : Becton Dickinson Microbiology Systems  
Becton Dickinson and Company  
250 Schilling Circle  
Cockeysville, MD

**Performance Data** : Oxoid Compound Sulphonamide Antimicrobial Susceptibility Test Discs perform in accordance with NCCLS Approved Performance Standard.

Code Number : S3 300  
Antimicrobial Content : 300µg

Product performance is in accordance with NCCLS Performance Standard for Antimicrobial Disk Susceptibility Tests - Fifth Edition Approved Standard - M2-A5 Vol. 13 No.24, and Performance Standards for 24, and Performance Standards for Antimicrobial Susceptibility Testing M100 - S6 Vol 15 No.14.

Data provided in this submission will be made available to any person within 30 days of a written request.



Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

DEC 23 1997

Andy Hollingsworth  
Quality Systems Manager  
Oxoid Limited  
Wade Road Basingstoke  
Hants RG24 8PW  
England

Re: K971637  
Trade Name: Oxoid Compound Sulphonamides Susceptibility Test Disc  
Regulatory Class: II  
Product Code: JTN  
Dated: November 17, 1997  
Received: November 20, 1997

Dear Mr. Hollingsworth:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>"

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

K971637

**510(K) Submission for  
Oxoid Antimicrobial Susceptibility Test Disc**

**COMPOUND SULPHONAMIDES**

**OXOID LTD**

---

**510(K) Summary**

DEC 23 1997

**510(K) Number :** K971637

**Product Name :** Compound Sulphonamides Susceptibility Test Disc

**Manufacturer :** Oxoid Limited  
Wade Road  
Basingstoke  
Hants RG24 8PW  
England

**Substantial Equivalence :**

Oxoid Compound Sulphonamide Antimicrobial Susceptibility Test Discs are substantially equivalent to other antimicrobial susceptibility test discs on the market.

**Product :** BBL Sensi-Disc Sulphonamides 300µg/mL  
Sensi -Disc - Antimicrobial Susceptibility Test Disc

**Manufacturer :** Becton Dickinson Microbiology Systems  
Becton Dickinson and Company  
250 Schilling Circle  
Cockeysville, MD

**Performance Data :** Oxoid Compound Sulphonamide Antimicrobial Susceptibility Test Discs perform in accordance with NCCLS Approved Performance Standard.

Code Number : S3 300  
Antimicrobial Content : 300µg

Product performance is in accordance with NCCLS Performance Standard for Antimicrobial Disk Susceptibility Tests - Fifth Edition Approved Standard - M2-A5 Vol. 13 No.24, and Performance Standards for 24, and Performance Standards for Antimicrobial Susceptibility Testing M100 - S6 Vol 15 No.14.

Data provided in this submission will be made available to any person within 30 days of a written request.



Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

DEC 23 1997

Andy Hollingsworth  
Quality Systems Manager  
Oxoid Limited  
Wade Road Basingstoke  
Hants RG24 8PW  
England

Re: K971637  
Trade Name: Oxoid Compound Sulphonamides Susceptibility Test Disc  
Regulatory Class: II  
Product Code: JTN  
Dated: November 17, 1997  
Received: November 20, 1997

Dear Mr. Hollingsworth:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>"

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

**510(K) Submission for  
Oxoid Antimicrobial Susceptibility Test Disc**

**COMPOUND SULPHONAMIDES**

**OXOID LTD**

---

**510(K) Number** : K971637

**Device Name** : Oxoid Compound Sulphonamide Susceptibility Test Disc

**Indication for Use** :

Antimicrobial Susceptibility Test Discs are indicated for the semi-quantitative susceptibility testing by agar diffusion test procedure of rapidly growing micro-organisms. These include : Enterobacteriaceae, Pseud. aeruginosa, Acinetobacter spp., and Staphylococcus spp.

The technical product insert details the Quality Control organisms to be use with this disc.

12/22/97  
John Tichauer MD, Interim Chief,  
(Division Sign-Off) Microbiol Branch  
Division of Clinical Laboratory Devices  
510(k) Number K971637

Prescription Use   
(Per 21 CFR 801.109)

OR

Over-The Counter Use

(Optional Format 1-2-96)